Julius Clinical strategically launched new operations in Spain and Germany, aiming to enhance regulatory expertise and access to patients in key European markets. The Netherlands-based CRO cites the countries’ innovation ecosystems and skilled professionals as vital to supporting efficient, high-quality clinical trial delivery. This expansion complements recent mergers and partnerships focused on CNS, cardiometabolic, renal, and infectious disease indications, signaling Julius’ commitment to evolving international therapeutic development capabilities.